Tech Company Financing Transactions
Amarantus BioScience Holdings Funding Round
On 9/3/2013, Amarantus BioScience Holdings raised $1.3 million in funding from private investors.
Transaction Overview
Company Name
Announced On
9/3/2013
Transaction Type
Venture Equity
Amount
$1,299,327
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing. Not a solicitation.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
45 Wall St. 920
New York, NY 10005
USA
New York, NY 10005
USA
Phone
Website
Email Address
Not Recorded
Overview
Amarantus BioScience Holdings, Inc. (NASDAQ: AMBS) is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gerald Commissiong
Chief Scientific Officer
John Commissiong
VP - Operations
Elise Brownell
VP - Regulatory Affairs
Brian Harvey
Browse more venture capital transactions:
Prev: 9/3/2013: Xambala venture capital transaction
Next: 9/3/2013: Lithium Technologies venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. All VC database entries on this site are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs